NasdaqGM:PTGXBiotechs
Protagonist Therapeutics (PTGX) Is Up 6.3% After Swing To Q2 Profitability And ESOP Usage Shift
In August 2026, Protagonist Therapeutics reported a sharp swing to profitability, posting second-quarter net income of US$162.85 million and diluted earnings per share from continuing operations of US$2.29, compared with a loss a year earlier.
Alongside this earnings turnaround, the company continued to utilize employee stock ownership plan shelf registrations, highlighting ongoing equity-based compensation as a meaningful part of its capital structure.
With this earnings reversal now on the...